title: In vivo amyloid imaging with PET in frontotemporal dementia.
abstract: BACKGROUND
  N-methyl[11C]2-(4'methylaminophenyl)-6-hydroxy-benzothiazole (PIB) is a positron emission tomography (PET) tracer with amyloid binding properties which allows in vivo measurement of cerebral amyloid load in Alzheimer's disease (AD). Frontotemporal dementia (FTD) is a syndrome that can be clinically difficult to distinguish from AD, but in FTD amyloid deposition is not a characteristic pathological finding.
  
  
  OBJECTIVE
  The aim of this study is to investigate PIB retention in FTD.
  
  
  METHODS
  Ten patients with the diagnosis of FTD participated. The diagnosis was based on clinical and neuropsychological examination, computed tomography or magnetic resonance imaging scan, and PET with 18 Fluoro-2-deoxy-d-glucose (FDG). The PIB retention, measured in regions of interest, was normalised to a reference region (cerebellum). The results were compared with PIB retention data previously obtained from 17 AD patients with positive PIB retention and eight healthy controls (HC) with negative PIB retention. Statistical analysis was performed with a students t-test with significance level set to 0.00625 after Bonferroni correction.
  
  
  RESULTS
  Eight FTD patients showed significantly lower PIB retention compared to AD in frontal (p < 0.0001), parietal (p < 0.0001), temporal (p = 0.0001), and occipital (p = 0.0003) cortices as well as in putamina (p < 0.0001). The PIB uptake in these FTD patients did not differ significantly from the HC in any region. However, two of the 10 FTD patients showed PIB retention similar to AD patients.
  
  
  CONCLUSIONS
  The majority of FTD patients displayed no PIB retention. Thus, PIB could potentially aid in differentiating between FTD and AD.
authors.affiliation: Department of Nuclear Medicine, Uruguay University Hospital of Clinics and Faculty of Science, Montevideo, Uruguay. henry.engler@medsci.uu.se
authors.forename: Henry
authors.initials: H
authors.lastname: Engler
authors.forename: Alexander Frizell
authors.initials: AF
authors.lastname: Santillo
authors.forename: Shu Xia
authors.initials: SX
authors.lastname: Wang
authors.forename: Maria
authors.initials: M
authors.lastname: Lindau
authors.forename: Irina
authors.initials: I
authors.lastname: Savitcheva
authors.forename: Agneta
authors.initials: A
authors.lastname: Nordberg
authors.forename: Lars
authors.initials: L
authors.lastname: Lannfelt
authors.forename: Bengt
authors.initials: B
authors.lastname: Långström
authors.forename: Lena
authors.initials: L
authors.lastname: Kilander
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000378:metabolism; D000682:Amyloid / Q000032:analysis* / Q000378:metabolism; D000814:Aniline Compounds; D052160:Benzothiazoles / Q000378:metabolism; D016022:Case-Control Studies; D003704:Dementia / Q000000981:diagnostic imaging* / Q000378:metabolism*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000682:Amyloid; D000814:Aniline Compounds; D052160:Benzothiazoles; D013844:Thiazoles